Paper Details
- Home
- Paper Details
Intranasal triamcinolone and growth velocity.
Author: AkbaryAkbar, BergerWilliam E, GawchikSandra M, QiuChunfu, SkonerDavid P
Original Abstract of the Article :
Inadequate designs and conflicting results from previous studies prompted the US Food and Drug Administration to publish guidelines for the design of clinical trials evaluating the effects of orally inhaled and intranasal corticosteroids on the growth of children. This study conformed to these guide...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1542/peds.2014-1641
データ提供:米国国立医学図書館(NLM)
Intranasal Triamcinolone and Growth Velocity: Evaluating the Impact on Children
The use of intranasal corticosteroids (INCS) is a common treatment for allergic rhinitis, but concerns have been raised about their potential impact on children's growth. This study, conducted in accordance with US Food and Drug Administration guidelines, evaluates the effect of intranasal triamcinolone acetonide (TAA-AQ) on the growth of children with perennial allergic rhinitis (PAR). The researchers sought to address the conflicting results of previous studies, providing a more definitive assessment of the potential growth effects of this commonly used medication.
Addressing Growth Concerns in Children with Allergic Rhinitis
This study provides valuable insights into the potential impact of intranasal triamcinolone acetonide on the growth of children with allergic rhinitis. The researchers' rigorous design, adhering to FDA guidelines, offers a more reliable assessment of the risks and benefits of this medication.
Navigating Treatment Decisions: Balancing Benefits and Risks
The study's findings are crucial for healthcare professionals when making treatment decisions for children with allergic rhinitis. The researchers' assessment of the growth effects of intranasal triamcinolone acetonide allows for a more informed approach to treatment, balancing the benefits of symptom control with potential risks to growth.
Dr.Camel's Conclusion
Like a desert traveler who must carefully choose their path, healthcare providers must weigh the benefits and risks of treatment options for children. This study provides valuable information about the potential growth effects of intranasal triamcinolone acetonide, empowering clinicians to make informed decisions about the best course of action for their young patients.
Date :
- Date Completed 2015-03-26
- Date Revised 2015-02-03
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.